Peapod Lane Capital LLC Takes $1.27 Million Position in Metagenomi, Inc. (NASDAQ:MGX)

Peapod Lane Capital LLC acquired a new position in Metagenomi, Inc. (NASDAQ:MGX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 351,213 shares of the company’s stock, valued at approximately $1,268,000.

Several other institutional investors have also added to or reduced their stakes in MGX. Geode Capital Management LLC boosted its position in Metagenomi by 105.8% during the third quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock valued at $734,000 after acquiring an additional 173,796 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Metagenomi by 209.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock valued at $296,000 after purchasing an additional 92,468 shares in the last quarter. Fortitude Advisory Group L.L.C. acquired a new stake in Metagenomi during the fourth quarter worth approximately $273,000. Spire Wealth Management bought a new stake in Metagenomi in the fourth quarter worth approximately $267,000. Finally, Marquette Asset Management LLC acquired a new position in Metagenomi in the fourth quarter valued at approximately $184,000.

Analyst Ratings Changes

Several analysts have recently commented on the stock. HC Wainwright raised their price objective on shares of Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th. Chardan Capital reissued a “buy” rating and set a $15.00 target price on shares of Metagenomi in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.67.

Metagenomi Stock Up 4.8 %

MGX stock opened at $2.39 on Thursday. Metagenomi, Inc. has a twelve month low of $1.61 and a twelve month high of $12.74. The stock has a 50-day simple moving average of $3.11 and a two-hundred day simple moving average of $2.71.

Metagenomi Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.